Conformis Reports First Quarter 2018 Financial Results
BILLERICA, Mass., May 02, 2018 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:CFMS), a medical technology company that uses its proprietary iFit Image-to-Implant technology platform to develop, manufacture and sell joint replacement implants that are customized to fit each patient's unique anatomy, announced today financial results for the first quarter ended March 31, 2018.
- Total revenue of $19.7 million, down 4% year-over-year on a reported basis and 6% on a constant currency basis
- Product revenue of $19.5 million, down 4% year-over-year on a reported basis and 6% on a constant currency basis
• U.S. product revenue of $16.0 million, consistent year-over-year
• Rest of World product revenue of $3.5 million, down 22% year-over-year on a reported basis and 30% year-over-year on a constant currency basis
- Gross margin of 45%, an increase of 1,300 basis points year-over-year
"As reported earlier, our first quarter revenue of $19.7 million was consistent with our revenue guidance. We continue to make progress in the US while facing headwinds in our OUS business due to reimbursement challenges,” said Mark Augusti, President and Chief Executive Officer of Conformis, Inc. “Importantly, our gross margin - which is a key imperative for us - increased to 45% for the quarter, a 1,300 basis point increase over the same quarter last year. This gross margin improvement is a reflection of our operational execution and we believe positions us well for the remainder of 2018.”
|Three months ended March 31,||Increase/(decrease)|
|($, in thousands)||2018||2017|| $
|(as reported)||(constant currency)|
|United States||$||16,027||$||15,964||$||63||— %||—|
|Rest of world||3,456||4,415||(959||)||(22)%||(30)%|
First Quarter 2018 Financial Results
Total revenue for the three-month period ended March 31, 2018 decreased $0.8 million to $19.7 million, or 4% year-over-year on a reported basis and 6% on a constant currency basis. Total revenue in the first quarter of 2018 and 2017 includes royalty revenue of $0.2 million and $0.1 million, respectively, related to patent license agreements.
Product revenue decreased $0.9 million to $19.5 million, or 4% year-over-year on a reported basis and 6% on constant currency basis. U.S. product revenue remained consistent at $16.0 million year-over-year, and Rest of World product revenue decreased $1.0 million to $3.5 million, or 22% year-over-year on a reported basis and 30% on a constant currency basis. Product revenue from sales of iTotal PS increased $0.7 million to $5.9 million or 13% year-over-year on a reported basis and 12% on a constant currency basis. Product revenue from sales of iTotal CR, iDuo and iUni decreased $1.6 million to $13.6 million, or 10% year-over-year on a reported basis and 12% on a constant currency basis. The decrease in product revenue was primarily in Germany, including the partial knee reimbursement rate change and weakness in iTotal CR sales.
Total gross profit increased $2.3 million to $8.8 million, or 45% of revenue, in the first quarter of 2018, compared to $6.5 million, or 32% of revenue, in the first quarter of 2017. This 1,300 basis point increase in gross margin year-over-year was driven mostly by cost reductions as a result of vertical integration and manufacturing efficiencies and higher year-over-year average selling prices, partly due to a favorable foreign exchange impact.
Total operating expenses decreased $2.6 million to $21.2 million, or 11% year-over-year. This decrease in expenses was driven primarily by a reduction in general and administrative expense.
Net loss was $12.0 million, or $0.22 per basic share, in the first quarter of 2018, compared to a net loss of $17.2 million, or $0.40 per basic share, for the same period last year. Net loss per basic share calculations assume weighted-average basic shares outstanding of 54.7 million for the first quarter of 2018, compared to 42.9 million for the same period last year.
As of March 31, 2018, cash and cash equivalents and investments totaled $57.3 million, compared to $45.2 million as of December 31, 2017. On January 29, 2018, the Company closed its follow on public offering of Company common stock, in which the Company received $23 million in gross proceeds, or $21.6 million in net proceeds, before legal and accounting expenses, from the sale of 15,333,333 shares of the Company’s common stock. This included an offering of 13.3 million shares of stock plus the exercise by our underwriters of the full overallotment, or Greenshoe, of 2 million shares.
Note on Non-GAAP Financial Measures
In addition to disclosing financial measures prepared in accordance with U.S. generally accepted accounting principles (GAAP), the Company provides certain information regarding the Company's financial results or projected financial results on a non-GAAP "constant currency basis." This information estimates the impact of changes in foreign currency rates on the translation of the Company's current or projected future period financial results as compared to the applicable comparable period. This impact is derived by taking the adjusted current or projected local currency results and translating them into U.S. Dollars based upon the foreign currency exchange rates for the applicable comparable period. It does not include any other effect of changes in foreign currency rates on the Company's results or business. Non-GAAP information is not a substitute for, and is not superior to, information presented on a GAAP basis.
As previously announced, Conformis will conduct a conference call and webcast today at 4:30 PM Eastern Time. Management will discuss financial results and strategic matters. To participate in the conference call, please call 877-809-6331 (or 615-247-0224 for international) and use conference ID number 1695267 or listen to the webcast in the investor relations section of the company's website at ir.conformis.com. The online archive of the webcast will be available on the company's website for 30 days.
About Conformis, Inc.
Conformis is a medical technology company that uses its proprietary iFit Image-to-Implant technology platform to develop, manufacture and sell joint replacement implants that are individually sized and shaped, or customized, to fit each patient's unique anatomy. Conformis offers a broad line of customized knee implants and pre-sterilized, single-use instruments delivered in a single package to the hospital. In clinical studies, Conformis iTotal CR demonstrated superior clinical outcomes, including better function and greater patient satisfaction, compared to traditional, off-the-shelf implants. Conformis owns or exclusively in-licenses issued patents and pending patent applications that cover customized implants and patient-specific instrumentation for all major joints.
Cautionary Statement Regarding Forward-Looking Statements
Statements in this press release about our future expectations, plans and prospects, including statements about the anticipated timing of our product launches, and our financial position and results, total revenue, product revenue, gross margin, operations, as well as other statements containing the words "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "might," "plan," "potential," "predict," "project," "should," "target," "will," or "would" and similar expressions, constitute forward-looking statements within the meaning of the safe harbor provisions of The Private Securities Litigation Reform Act of 1995. We may not actually achieve the forecasts disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements. Actual financial results could differ materially from the projections disclosed in the forward-looking statements we make as a result of a variety of risks and uncertainties, including risks related to our estimates and expectations regarding our revenue, gross margin, expenses, revenue growth and other results of operations, and the other risks and uncertainties described in the "Risk Factors" sections of our public filings with the Securities and Exchange Commission. In addition, the forward-looking statements included in this press release represent our views as of the date hereof. We anticipate that subsequent events and developments may cause our views to change. However, while we may elect to update these forward-looking statements at some point in the future, we specifically disclaim any obligation to do so. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date hereof.
|CONFORMIS, INC. AND SUBSIDIARIES|
|Consolidated Statements of Operations|
|(in thousands, except share and per share data)|
|Three Months Ended
|Cost of revenue||10,869||13,960|
|Sales and marketing||10,411||10,816|
|Research and development||4,694||4,560|
|General and administrative||6,140||8,458|
|Total operating expenses||21,245||23,834|
|Loss from operations||(12,458||)||(17,339||)|
|Other income and expenses|
|Foreign currency exchange transaction income||1,085||390|
|Total other expenses||490||186|
|Loss before income taxes||(11,968||)||(17,153||)|
|Income tax provision||33||7|
|Net loss per share - basic and diluted||$||(0.22||)||$||(0.40||)|
|Weighted average common shares outstanding - basic and diluted||54,741,828||42,874,743|
|CONFORMIS, INC. AND SUBSIDIARIES|
|Consolidated Balance Sheets|
|(in thousands, except share and per share data)|
|Cash and cash equivalents||$||38,078||$||18,348|
|Accounts receivable, net||12,089||13,200|
|Prepaid expenses and other current assets||2,231||2,246|
|Total current assets||79,781||69,858|
|Property and equipment, net||16,890||16,514|
|Intangible assets, net||185||210|
|Other long-term assets||23||23|
|Liabilities and stockholder's equity|
|Total current liabilities||13,413||12,916|
|Other long-term liabilities||648||651|
|Deferred tax liabilities||20||37|
|Long-term debt, less debt issuance costs||29,694||29,667|
|Commitments and contingencies||—||—|
|Preferred stock, $0.00001 par value:|
|Authorized: 5,000,000 shares authorized at March 31, 2018 and December 31,
2017; no shares issued and outstanding as of March 31, 2018 and December 31,
|Common stock, $0.00001 par value:|
|Authorized: 200,000,000 shares authorized at March 31, 2018 and December 31,
2017; 60,838,526 and 45,528,519 shares issued and outstanding at March 31, 2018
and December 31, 2017, respectively
|Additional paid-in capital||508,767||486,570|
|Accumulated other comprehensive loss||(4,168||)||(3,236||)|
|Total stockholders' equity||60,297||46,513|
|Total liabilities and stockholders' equity||$||104,072||$||93,798|